Literature DB >> 20159585

Disturbed regulatory T cell homeostasis in multiple sclerosis.

Koen Venken1, Niels Hellings, Roland Liblau, Piet Stinissen.   

Abstract

The pathological features of multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system, support an autoimmune etiology. Strong evidence has been provided for a potential functional defect of CD4(+)CD25(+)FOXP3(+) regulatory T cells (Tregs) in patients with relapsing-remitting MS. More recently, alterations in homeostatic parameters related to the development and function of naive and memory-like Tregs were discovered in MS patients. In this review, we evaluate the evidence for disturbed Treg homeostasis in MS and discuss the role of potential compensatory mechanisms in the chronic disease phase. Better insights into the processes underlying the compromised immune regulation in MS patients will be important to understand the potential of Treg-based therapies.

Entities:  

Mesh:

Year:  2010        PMID: 20159585     DOI: 10.1016/j.molmed.2009.12.003

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  56 in total

1.  Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system.

Authors:  Roxana del Rio; Rajkumar Noubade; Naresha Saligrama; Emma H Wall; Dimitry N Krementsov; Matthew E Poynter; James F Zachary; Robin L Thurmond; Cory Teuscher
Journal:  J Immunol       Date:  2011-12-05       Impact factor: 5.422

Review 2.  Inflammation and adaptive immunity in Parkinson's disease.

Authors:  R Lee Mosley; Jessica A Hutter-Saunders; David K Stone; Howard E Gendelman
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

3.  Disease exacerbation of multiple sclerosis is characterized by loss of terminally differentiated autoregulatory CD8+ T cells.

Authors:  Khrishen Cunnusamy; Ethan J Baughman; Jorge Franco; Sterling B Ortega; Sushmita Sinha; Parul Chaudhary; Benjamin M Greenberg; Elliot M Frohman; Nitin J Karandikar
Journal:  Clin Immunol       Date:  2014-03-20       Impact factor: 3.969

4.  Immunomodulatory function of Treg-derived exosomes is impaired in patients with relapsing-remitting multiple sclerosis.

Authors:  Maryam Azimi; Mojdeh Ghabaee; Abdorreza Naser Moghadasi; Farshid Noorbakhsh; Maryam Izad
Journal:  Immunol Res       Date:  2018-08       Impact factor: 2.829

5.  Vitamin D and multiple sclerosis hospital admissions in Scotland.

Authors:  G Disanto; A E Handel; J M Morahan; G C Deluca; S M Kimball; E Hypponen; G Giovannoni; G C Ebers; S V Ramagopalan
Journal:  QJM       Date:  2011-06-29

6.  CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis.

Authors:  Crisol Álvarez-Quiroga; Carlos Abud-Mendoza; Lesly Doníz-Padilla; Amida Juárez-Reyes; Adriana Monsiváis-Urenda; Lourdes Baranda; Roberto González-Amaro
Journal:  J Clin Immunol       Date:  2011-04-13       Impact factor: 8.317

7.  Multiple sclerosis: Repurposing dopaminergic drugs for MS--the evidence mounts.

Authors:  Franca Marino; Marco Cosentino
Journal:  Nat Rev Neurol       Date:  2016-03-29       Impact factor: 42.937

Review 8.  Circulating immune cells in multiple sclerosis.

Authors:  A P Jones; A G Kermode; R M Lucas; W M Carroll; D Nolan; P H Hart
Journal:  Clin Exp Immunol       Date:  2016-11-02       Impact factor: 4.330

Review 9.  Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?

Authors:  Marco Cosentino; Franca Marino
Journal:  J Neuroimmune Pharmacol       Date:  2012-10-17       Impact factor: 4.147

Review 10.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.